Biomea Fusion reports icovamenib shows C-peptide gains in type 1 diabetes

April 27, 2026 5:37 PM

Biomea Fusion Inc. (NASDAQ: BMEA) announced 52-week results from its Phase 2 COVALENT-112 trial testing icovamenib in patients with type ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found